Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

American Journal of Surgery

Volumn 196, Issue 4, 2008, Pages 527-529

  Asad, Juhi ^a,b   Jacobson, Allyson F ^a,b   Estabrook, Alison ^a   Smith, Sharon Rosenbaum ^a   Boolbol, Susan K ^b   Feldman, Sheldon M ^b   Osborne, Michael P ^b   Boachie Adjei, Kwadwo ^b   Twardzik, Wendy ^a   Tartter, Paul I ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

21 gene; Assay; Breast cancer; Management; Recurrence score

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER STAGING; EARLY CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; ONCOGENE NEU; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SCORING SYSTEM; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 52049089470     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2008.06.021     Document Type: Article

References (6)

1. Fisher B., Jeong J.H., Bryant J., et al. Treatment of lymph node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. Lancet 364 (2004) 858-868
2. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 (2006) 3726-3734
3. Wolf I., Baruch N.B., Shapira-Frommer R., et al. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients. Cancer 112 (2008) 731-736
4. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
5. Lo S.S., Norton J., Mumby P.B., et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 25 (2007) 577
6. Erb C, Fox KR, Patel M, et al. Evaluation of practice patterns in the treatment of node-negative, hormone-receptor positive breast cancer patients with the use of the Oncotype DX assay at the University of Pennsylvania. Abstract [no. 3082] presented at The 2007 San Antonio Breast Cancer Symposium, San Antonio, TX, December 13 to 16, 2007.